Drugs / FEXAPOTIDE
FEXAPOTIDE
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01620515 | Feb 2012 → Oct 2015 | prostate cancer | Nymox Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00759135 | May 2007 → Jan 2008 | benign prostatic hyperplasia | Nymox Corporation | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT02003742 | Sep 2013 → Jan 2015 | — | RECORDATI GROUP | Terminated | No outcome recorded |
| Phase 3 | NCT01846793 | Apr 2013 → Oct 2014 | benign prostatic hyperplasia | Nymox Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01438775 | Sep 2011 → Jan 2013 | benign prostatic hyperplasia | Nymox Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00945490 | May 2009 → May 2014 | benign prostatic hyperplasia | Nymox Corporation | Completed | Mixed |
| Phase 3 | NCT00918983 | Apr 2009 → Nov 2013 | benign prostatic hyperplasia | Nymox Corporation | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2016-02-09 | Nymox Corporation | Results Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study nymox.com ↗
Cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups. |
| 2015-07-27 | Nymox Corporation | Results Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File For Regulatory Approvals For Fexapotide Triflutate (NX-1207). nymox.com ↗ |
| 2015-04-20 | Nymox Corporation | Results Nymox Announces New Prostate Cancer Clinical Trial Results nymox.com ↗
The new results demonstrate statistically significant (p=.0067) better outcomes at up to 2.8 years for NX- 1207 treated patients compared to controls. |
| 2014-11-02 | Nymox Corporation | Results Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02- 0018 Fail to Meet Primary Efficacy Endpoints nymox.com ↗ |
| 2014-09-10 | Nymox Corporation | Results Nymox Announces Positive Prostate Cancer 8 Month Clinical Trial Results nymox.com ↗ |
| 2014-07-22 | Nymox Corporation | Results Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH nymox.com ↗
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce new positive efficacy data for U.S. Study NX02-0022, the Company’s repeat injection study of NX-1207 for BPH. |
| 2014-06-17 | Nymox Corporation | Results Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207 nymox.com ↗
A detailed study of prostate tissues from men who had received intraprostatic injections of NX-1207 2.5 mg or 15 mg found that nervous tissues in the prostate after treatment were left intact and showed no damage. |
| 2014-06-11 | Nymox Corporation | Results Nymox Reports Positive New Safety Study Data For Phase 3 BPH Drug nymox.com ↗
These results are consistent with the pharmacological profile of the drug and with the extensive body of safety data from the more than 1,000 men treated with the drug to date demonstrating the absence of any significant drug-related side effects. |
| 2014-05-21 | Nymox Corporation | Results Nymox Reports New Results on Favorable Side Effect Profile of NX-1207 Treatment nymox.com ↗ |
| 2014-05-13 | Nymox Corporation | Results Nymox Reports Positive Results Showing That NX-1207 Treatment for Prostate Cancer Does Not Affect Testosterone Levels nymox.com ↗
Analysis of testosterone levels post-treatment for men treated with NX-1207 2.5 mg (n=47) or 15 mg (n=46) showed no statistically significant change as compared to control active surveillance patients (n=48). |
| 2014-05-06 | Nymox Corporation | Results Nymox Announces Positive New Prostate Cancer Clinical Trial Results nymox.com ↗ |
| 2014-04-30 | Nymox Corporation | Results Nymox Reports Top-Line Results for Localized Prostate Cancer Study nymox.com ↗ |
All press releases naming this drug 46 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FEXAPOTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545061 ↗ |
| Known as | Fexapotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545061 ↗ |
| Known as | NX-1207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00945490 ↗ |
| Known as | NYM-4805 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545061 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL3545061 ↗ |
| Route | Other | “single intraprostatic injection of 2.5 mg NX-1207” NCT00759135 ↗ |